Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

PRIMARY OBJECTIVES:

I. To assess and compare the pathologic complete response (PCR) rate of patients in Arm A
receiving the sequence docetaxel, oxaliplatin, and capecitabine (DOC) followed by
5-fluorouracil (5-FU), oxaliplatin, and radiation therapy (RT) with patients in Arm B
receiving only 5-FU, oxaliplatin and RT in patients with potentially resectable
adenocarcinoma (ACA) of the esophagus, gastroesophageal junction (GEJ), or gastric cardia.

SECONDARY OBJECTIVES:

I. To assess the adverse event (AE) profile and safety of the proposed treatment in this
population.

II. To assess and compare the overall survival (OS) between treatment arms. III. To assess
and compare the disease-free survival between treatment arms. IV. To assess and compare the
clinical tumor response rate of the proposed regiments when administered before surgery
between treatment arms.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive docetaxel intravenously (IV) over 1 hour and oxaliplatin IV over 2
hours on day 1. Patients also receive capecitabine orally (PO) twice daily (BID) on days
1-14. Treatment repeats every 21 days for 2 courses in the absence of disease progression or
unacceptable toxicity. After completion of the second course, patients receive fluorouracil*
IV continuously on days 1-5 and oxaliplatin IV over 2 hours on days 1, 15, and 29. Patients
also undergo radiotherapy** 5 days a week for 5.5 weeks in the absence of disease progression
or unacceptable toxicity. Approximately 4-12 weeks after completion of radiotherapy, patients
undergo surgery.

ARM II: Patients receive fluorouracil IV continuously on days 1-5 and oxaliplatin IV over 2
hours on days 1, 15, and 29. Patients also undergo radiotherapy and then surgery as in Arm I.

- NOTE: * Fluorouracil continuous IV infusion begins within 24 hours of radiotherapy and
ends within 24 hours of radiotherapy completion.

- NOTE: ** Radiotherapy should begin within 2-6 weeks after completion of 2 courses of
docetaxel, oxaliplatin, and capecitabine.

After completion of study treatment, patients are followed up every 3 months for 2 years.

Inclusion Criteria

- Histological confirmation of adenocarcinoma of the esophagus, gastroesophageal (GE)
junction, or gastric cardia

- Tumor must be considered surgically resectable; Note: patients with T4N0M0 tumors that
are potentially resectable are also eligible

- Nodal involvement: patients with involvement of celiac nodes, (stations 15-20) are
eligible if the primary lesion is mid-thoracic, distal esophagus or GE junction;
patients with supraclavicular node involvement are eligible with upper thoracic
esophagus primary lesions

- Capable of swallowing pills

- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2

- Absolute neutrophil count (ANC) >= 1500

- Peripheral platelet count >= 100,000

- Hemoglobin >= 9.0 g/dL

- Total bilirubin =< 1.5 x upper normal limit (UNL)

- Serum glutamic oxaloacetic transaminase (SGOT) (alanine aminotransferase [AST]) =< 3 x
UNL

- Creatinine =< 1.5 x UNL

- Negative pregnancy test done =< 7 days prior to registration, for women of
childbearing potential only

- Provide informed written consent

- Willingness to return to NCCTG enrolling institution for follow-up

- Patient willing to provide mandatory tissue and blood samples for research purposes

- Patient willing to allow use of FDG PET/CT scans for mandatory research purposes

Exclusion Criteria

- Evidence of distant metastases

- Palpable supraclavicular nodes, biopsy-proven involvement of supraclavicular nodes, or
radiographically involved supraclavicular nodes (> 1.5 cm in greatest dimension) for
lesions in mid-thoracic, distal thoracic or GE junction

- T1N0M0 or T2N0M0 tumor stage

- Any of the following

- Pregnant women

- Nursing women

- Men or women of childbearing potential who are unwilling to employ adequate
contraception

- Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment
of the investigator, would make the patient inappropriate for entry into this study or
interfere significantly with the proper assessment of safety and toxicity of the
prescribed regimens

- Immunocompromised patients (other than that related to the use of corticosteroids)
including patients known to be human immunodeficiency virus (HIV) positive

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements

- Uncontrolled diabetes (i.e., will interfere with the performance of the FDG PET/CT
scans)

- Receiving current treatment or prior treatment for this malignancy

- Other active malignancy 5 years prior to registration, except non-melanotic skin
cancer or carcinoma-in-situ of the cervix; if there is a history of prior malignancy,
patient must not be receiving other specific treatment (other than hormonal therapy)
for cancer

- Prior radiation to > 30% of the marrow cavity